张治华;邓雪峰;李建平;张俊成;

• 1:广州白云心理医院

摘要(Abstract)：

目的:探讨帕利哌酮缓释片联合碳酸锂对双相抑郁障碍患者的临床疗效和安全性。方法:选取60例双相抑郁障碍患者,随机分为帕利哌酮缓释片+碳酸锂联合治疗组(研究组)和碳酸锂单药治疗组(对照组),每组各30例,治疗期均为8周。采用17项汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD-17)、治疗副反应量表(Treatment Emergent Symptom Scale,TESS)对比分析治疗2周、4周及8周后两组的临床疗效。结果:两组患者对比:基线期HAMD-17评分差异无统计学意义(P>0.05)。治疗2周及4周后研究组较对照组HAMD-17评分下降更明显,差异有统计学意义(P<0.05)。治疗8周后,研究组和对照组HAMD-17评分比较差异无统计学意义(P>0.05)。两组不良反应比较,第2周末差异有统计学意义(P<0.05),第4周末和第8周末差异无统计学意义(P>0.05)。结论:帕利哌酮缓释片联合碳酸锂治疗双相抑郁障碍较单用碳酸锂起效更快,不良反应相当。

关键词(KeyWords)： 双相抑郁障碍;帕利哌酮缓释片;碳酸锂;临床疗效

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张治华;邓雪峰;李建平;张俊成;

Email:

DOI:

参考文献(References)：

• [1]Merikangas KR,Akiskal HS,Angst J,et al.Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication[J].Arch Gen Psychiatry,2007,64(5):43-552.
• [2]Post RM.The impact of bipolar depression[J].J Clin Psychiatry,2005,66(5):5-10.
• [3]童建明.非典型抗精神病药能成为新型心境稳定剂吗[J].国际精神病学杂志,2010,37(1):43-46.
• [4]Yatham LN,Kennedy SH,Schaffer A.Canadian network for mood and anxiety treatments(CANMAT)and international society for bipolar disorders(ISBD)coilaborative update of CANMAT guidelines for the management of patients with bipolar disorder;update2009[J].Bipolar Disord,2009,11(3):225-255.
• [5]幸村州洋,岩本邦弘,尾崎纪夫.双相性障碍的药物疗法update[J].临床精神医学,2011,40(3):317-326.
• [6]喻东山,高振忠.精神科合理用药手册[M].南京:江苏科学技术出版社,2005:152-153.
• [7]Conley R,Gupta SK,Sathyan G.Clinical spectrum of the osmotic-controlled release oral delivery system(OROS),an advanced oral delivery form[J].Curr Med Res Opin,2006,22:1879-1892.
• [8]Yatham LN,Goldstein JM,Vieta E,et al.Atypical antipsychotics in bipolar depression;potential mechanisms of action[J].J Clin Psychiatry,2005,66(5):40-48.
• [9]Calabrese JR,Elhaj O,Gajwani P,et al.Clinical highlights in bipolar depression:focus on atypical antipsychotics[J].J Clin Psychiatry,2005,66(5):26-33.
• [10]Compton MT,Nemeroff CB.The treatment of bipolar depression[J].Clin Psychiatry,2006,61(9):57-67.
• [11]Ketter TA.Monotherapy versus combined treatment with secondgeneration antipsychotics in bipolar disorder[J].J Clin Psychiatry,2008,69(Suppl5):9-15.
• [12]Marino J,English C,Caballero J,et al.The role of paliperidone extended release for the treatment of bipolar disorder[J].Neuropsychiatr Dis Treat,2012,8:181-9.
• [13]Berwaerts J,Melkote R,Nuamah I,et al.A randomized,placebo-and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode[J].J Affect Disord,2012,138(3):247-58.
• [14]Joshi G,Petty C,Wozniak J,et al.A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents[J].Psychopharmacology(Berl),2013,227(3):449-58.
• [15]舒良,蔡焯基,吉中孚,等.帕利哌酮缓释片临床用药指导意见[J].中国新药杂志,2011,20(16):1514-1521.